Danzhou

Researchers are evaluating the effectiveness of nucresiran compared to a placebo in reducing death from any cause and cardiovascular events in patients with transthyretin amyloidosis that affects the heart. The study also aims to assess how nucresiran impacts additional cardiovascular events, mortality, and patient-reported health status and quality of life. This is a Phase 3, global, randomized, double-blind, placebo-controlled trial focusing on this serious heart condition. Participants will receive either nucresiran 300 mg or a placebo (sterile normal saline) via subcutaneous injection every six months. The study treatment period is expected to last about 32 months, with a maximum duration of up to 5 years. Both groups will be monitored closely throughout this time, and patients may continue other approved therapies for transthyretin amyloidosis and heart failure as recommended by their doctors. During the study, participants will undergo regular assessments to track all-cause mortality and recurrent cardiovascular events, including hospitalizations and urgent visits for heart failure. Other evaluations will include patient-reported health outcomes and quality of life measurements. Researchers will monitor safety and treatment effects over the full study period, with a focus on how well nucresiran may improve health and reduce cardiovascular complications in this patient population.